sellWeak cluster of 5
Paul K. Audhya sold $83k of KALV
CHIEF MEDICAL OFFICER at KalVista Pharmaceuticals, Inc.. 5,354 shares at an average of $15.57, traded Feb 23, 2026, filed Feb 24, 2026.
Warning score
24Value
$83k
5,354 shares
Holdings after
138,983
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +9Trade size$83k at market
- 0Share of holdings soldSold 3.7% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001860131-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 21, 2026 | MOption exercise Common Stock | +6,250 | - | - | 139,337 | Feb 24, 2026 |
| Feb 22, 2026 | MOption exercise Common Stock | +5,000 | - | - | 144,337 | Feb 24, 2026 |
| Feb 23, 2026 | SOpen-market sale Common Stock | -5,354 | $15.57 | $83k | 138,983 | Feb 24, 2026 |
| Feb 21, 2026 | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 75,000 | Feb 24, 2026 |
| Feb 22, 2026 | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 45,000 | Feb 24, 2026 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $60k 2,239 shares | -1% | |
| 8Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $72k 2,685 shares | -2% | |
| 5Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $28k 1,032 shares | -1% | |
| 7Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $54k 2,686 shares | -2% | |
| 37Weak | KALVsell KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. owner | $3.7M 214,631 shares | -4% | |
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $108k 6,693 shares | -1% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $156k 10,034 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $68k 4,347 shares | -2% | |
| 32Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $28k 1,767 shares | -11% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $62k 3,975 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.